Bristol's CheckMate 067 Revives Debate On Rationing Yervoy/Opdivo Combo
Executive Summary
Yervoy/Opdivo combo proves significant survival benefit over Yervoy alone in Phase III frontline melanoma study, but is on par with Opdivo alone in patients with higher PD-L1 expression.
You may also be interested in...
Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize
Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.
Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize
Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.
PD-1 Earnings Roundup: Buckle Up For A Bumpy Ride
Results from a number of Phase III studies in non-small cell lung cancer for major immuno-oncology players are coming soon, with potential to change the market dynamics.